Replies to post #250640 on Biotech Values

[Mufaso]

VKTX is up to a new all time high midday on another rumor of a buyout (Likely short covering):

Ben Harrington's Betaville blog highlighted a rumor related to Viking Therapeutics, contacts tell The Fly. The M&A-focused blog had also highlighted a Viking Therapeutics rumor on January 31.

Read more at:
https://thefly.com/n.php?id=3865434

Twitter also active. The post below has some good info to show how VK2735 will be compared to Tirzepatide in it's Surmount 1 obesity (non-diabetic population) study . You need to click on the photo to see the whole graph. The data for VK2735 is from the old phase 1 study and that was a really small data set. The Venture data is the info we should get very soon and will be the real comparison going forward as it is a reasonably sized phase 2 going out to 13 weeks of dosing (with 6 weeks of follow-up monitoring that should be known at time of the data reading out publicly):

Here’s another money slides
These slides tells you how undervalued $VKTX if we compare current market cap vs what $LLY gained market cap from obesity ramp up (350 Billion plus)

No need to click anywhere, just take a peek at data comparison, dose titrations, rate of… pic.twitter.com/tlRNQbQF88

— Pharmdca (@Pharmdca) February 16, 2024